A phosphoproteomic signature in endothelial cells predicts vascular toxicity of tyrosine kinase inhibitors used in CML

Newer CML kinase inhibitors increase ischemia risk and are toxic to endothelial cells where they produce a proteomic toxicity signature. This phosphoproteomic EC toxicity signature predicts bosutinib to be safe, providing a potential screening tool for safer drug development.

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Gopal, Srila, Lu, Qing, Man, Joshua J., Baur, Wendy, Rao, Sitara P., Litichevskiy, Lev, Papanastasiou, Malvina, Creech, Amanda L., DeRuff, Katherine C., Mullahoo, James, Officer, Adam, Egri, Shawn B., Davison, Desiree, Jaffe, Jacob D., Jaffe, Iris Z.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2018
Assuntos:
Stimulus Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6058230/
https://ncbi.nlm.nih.gov/pubmed/30021779
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018020396
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados